Santhera's Shareholders Approve all Board Proposals at Annual Shareholders' Meeting
(Thomson Reuters ONE) -
Santhera Pharmaceuticals Holding AG /
Santhera's Shareholders Approve all Board Proposals at Annual Shareholders'
Meeting
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Liestal, Switzerland, April 4, 2017 - Santhera Pharmaceuticals (SIX: SANN)
announces that a large majority of shareholders approved all proposals by the
Board of Directors at the Annual Shareholders' Meeting (ASM) today.
Participating shareholders represented a total of 3,097,267 shares or 49.3% of
the share capital with voting power.
"The results of today's ASM are a strong vote of confidence in our strategy and
performance and I thank our shareholders for their consent and continued
support," said Martin Gertsch, Chairman of the Board of Directors until today's
ASM. "2016 was exceptionally successful and Santhera's first full year as a
commercial company following the European marketing authorization for Raxone(®).
Today, backed by sufficient financial resources, Santhera is well positioned for
further milestone achievements and strong international growth. Against this
background, I welcome the newly elected members of the Board of Directors, who,
with their complementary diverse industry experience and know-how, will further
contribute to the successful implementation of our development, commercial and
strategic goals."
Approval of the annual and consolidated financial statements 2016 and result
appropriation
The shareholders endorsed the annual financial statements and the consolidated
financial statements for 2016 and the appropriation of the net result of CHF -
894,664 to new account. Furthermore, the shareholders granted discharge to the
members of the Board of Directors and Executive Management for the financial
year 2016.
Increase of conditional capital approved
The shareholders approved the increase of the conditional capital for employee
participations thereby supporting the expansion of the organization with
qualified staff and strengthening the attractiveness of Santhera as an employer.
Furthermore, the shareholders consented to an increase of conditional capital
for financings enabling the Company for a future delivery of shares under the
conditions of the convertible bond issued on February 10, 2017, solely from
conditional capital.
Elections of Board of Directors, Chairman and Compensation Committee
Shareholders re-elected Martin Gertsch and newly elected Philipp Gutzwiller,
Thomas Meier, Elmar Schnee and Patrick Vink as members of the Board of
Directors, each for a term of one year. In addition, shareholders elected Elmar
Schnee as Chairman of the Board of Directors. Furthermore, the shareholders
elected Elmar Schnee and Patrick Vink as members of the Compensation Committee.
The newly elected Chairman of the Board of Directors Elmar Schnee said: "Today,
I assume my new role with great optimism and I would like to thank the
shareholders for their confidence. At the same time, I wish to express my
recognition to the previous Board, management and all employees for their
outstanding efforts in developing Santhera into the promising and well
positioned specialty pharma company it is today. I am looking forward to working
with the Board of Directors and the Executive Management to further pursue the
growth strategy and strengthening Santhera as a leader in the treatment of
mitochondrial diseases."
Board and Executive Management remuneration approved
In three separate binding votes, Santhera's shareholders agreed to the maximum
total amount of fixed compensation for members of the Board of Directors
covering the period from the ASM 2017 to the ASM 2018 as well as the maximum
total amount of fixed compensation 2018 and variable compensation 2016 for the
members of the Executive Management. Furthermore, in a consultative vote,
shareholders endorsed the Compensation Report 2016.
Details on the agenda items
The proposals and explanations about the agenda items are available on the
Company's website at http://www.santhera.com/investors-and-media/investor-
toolbox/shareholder-meetings. From end of this week, the protocol of the ASM
2017 will also be available.
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company
focused on the development and commercialization of innovative pharmaceutical
products for the treatment of orphan mitochondrial and neuromuscular diseases.
Santhera's lead product Raxone(®) is authorized in the European Union, Norway,
Iceland and Liechtenstein for the treatment of Leber's hereditary optic
neuropathy (LHON). For Duchenne muscular dystrophy (DMD), the second indication
for Raxone, Santhera has filed a Marketing Authorization Application (MAA) in
the European Union and Switzerland. In collaboration with the US National
Institute of Neurological Disorders and Stroke (NINDS) Santhera is developing
Raxone in a third indication, primary progressive multiple sclerosis (PPMS), and
omigapil for congenital muscular dystrophy (CMD), all areas of high unmet
medical need. For further information, please visit the Company's website
www.santhera.com.
Raxone(®) is a trademark of Santhera Pharmaceuticals.
For further information, contact:
Thomas Meier, PhD, Chief Executive Officer Christoph Rentsch, Chief
Financial Officer
Phone +41 61 906 89 64 Phone
+41 61 906 89 65
thomas.meier(at)santhera.com
christoph.rentsch(at)santhera.com
US investor contact US Public Relations
contact
Hans Vitzthum, LifeSci Advisors, LLC John Gillespie, Medical
Dynamics
Phone +1 212 915 2568 Phone
+1 646 599 8626
hans(at)lifesciadvisors.com
jgillespie(at)rxmedyn.com
Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks, uncertainties
and other factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially different from those
expressed or implied by such statements. Readers should therefore not place
undue reliance on these statements, particularly not in connection with any
contract or investment decision. The Company disclaims any obligation to update
these forward-looking statements.
# # #
News Release ASM 2017:
http://hugin.info/137261/R/2093528/791367.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 04.04.2017 - 12:48 Uhr
Sprache: Deutsch
News-ID 534379
Anzahl Zeichen: 8086
contact information:
Town:
Liestal
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 102 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Santhera's Shareholders Approve all Board Proposals at Annual Shareholders' Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
Santhera Pharmaceuticals Holding AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
